One of the most challenging aspects of obesity is its link to "metabolic syndrome," when abdominal obesity is accompanied by high fasting blood glucose, low levels of high-density lipoprotein cholesterol, high levels of triglycerides, and elevated blood pressure. With rising obesity rates, metabolic syndrome is likely to become more common in the years ahead (1) . Although progress has been made in identifying this syndrome's individual components, their interplay across several organ systems is not well understood; that is, the near-linear relationship between body mass index and blood pressure. Obesity is often recognized as a predictor of treatment-resistant hypertension (2) . One of the main endocrine pathways that has been implicated involves natriuretic peptides (3) . Natriuretic peptides exert their antihypertensive effects predominantly by inducing natriuresis but have additional effects beyond blood pressure regulation. For example, an antihypertrophic effect, independent of blood pressure, was observed in the heart (4). Other reports demonstrate the ability of atrial natriuretic peptide (ANP) to promote lipolysis (5) and activate the brown fat thermogenic program (6) . Notably, levels of natriuretic peptides are lower in obese subjects and patients with type 2 diabetes (7).
Genetic studies demonstrated that the single nucleotide polymorphism rs5068 (A/G) is most strongly associated with plasma ANP levels. Carriers of the minor G allele are less obese, have a lower risk of hypertension, and a decreased incidence of cardiovascular events (8) . In this issue of the Journal, Arora et al. Thus, in patients with advanced HF, miR-425-independent mechanisms appear to be at work, and miR-425 might fine tune, rather than determine, levels of ANP expression.
One of the recent landmark clinical trials in cardiovascular disease evaluated a neprilysin inhibitor, targeting the endopeptidase that degrades the natriuretic peptides (among others), which was chemically linked to an angiotensin receptor blocker (16) .
The impressive reduction of hospitalization for HF, as well as death from cardiovascular causes, might be explained, at least in part, by increasing ANP levels in the intervention group. Given this emerging new gold standard in clinical care, it is questionable whether miR-425 inhibitors would have therapeutic potential for raising ANP (10) . Pharmacological modulation of miRNA expression can be successfully achieved (17) . However, miRNA therapeutics face major challenges in that single base changes may profoundly affect toxicology, and off-target effects can occur due to the ubiquitous expression of most miRNAs. Also, there are difficulties in establishing the correct dosing regimen, demonstrating target engagement, and ensuring efficient delivery, in particular to the heart. Oligonucleotides tend to accumulate in the liver and the kidney. This build-up could become a concern during prolonged treatment for chronic conditions, such as metabolic syndrome.
In summary, Arora et al. (9) presented evidence for a mechanism whereby glucose intake induced miR-425 expression, which in turn decreased ANP levels, potentially contributing to hypertension and other deleterious effects in cardiometabolic disease.
Although a definitive pathophysiological link between miR-425, obesity, diabetes, and ANP levels is not yet established, this study does add to the compelling evidence that miRNAs are part of important regulatory mechanisms in cardiometabolic diseases that merit further investigation (18) . 
